## MTN-016

## HIV Prevention Agent Pregnancy Exposure Registry

#### **Protocol Co-Chairs:**

Richard Beigi, MD, MSc

Magee-Womens Hospital, Pittsburgh USA

Samuel Kabwigu, MBChB, MMED

Makerere University, Kampala Uganda



### MTN-016

#### **EMBRACE:**

# Evaluation of Maternal and Baby Outcomes Registry After Chemoprophylactic Exposure



## **Study Population**

- Participants who become or became pregnant during HIV prevention trials, or who have or had planned exposures in pregnancy safety studies, provided pregnancy outcome was <1 year from the date of the EMBRACE Screening/Enrollment Visit
  - Target enrollment = 500 women
- The infants resulting from those pregnancies, provided infants have not yet reached their 1 year birth date.
  - Target enrollment = 300 live infants



#### **Primary Objectives**

- Pregnancy loss: mothers exposed/not exposed to an active study agent
- Major malformations: infants exposed/not exposed to active study agent in utero



#### **Secondary Objectives**

- Adverse pregnancy outcomes
- Growth parameters: infants exposed/not exposed to active study agent in utero
- Major malformations: infants exposed/not exposed to active study agent in utero

#### **Exploratory Objectives**

- Select risks of prevention agents by trimester of exposure
- Prevalence/persistence of HIV drug mutations in HIVinfected infants
- Developmental screening: infants exposed/not exposed to active study agent in utero




#### Expected MTN parent protocols:

- MTN-002: Ph 1 Maternal Single-Dose PK and Placental transfer of Tenofovir 1% Vaginal gel among Healthy Term Gravidas
  - N = 16 mother-infant pairs
- MTN-008: Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation
  - N = 90 mother-infant pairs
- MTN-003: VOICE
  - Expected to contribute the remainder



## MTN016 Participant Contributors



#### **Main Maternal Inclusion Criterion**

 During participation in parent protocol, has/had known confirmed pregnancy

#### **Maternal Exclusion Criteria**

- Any condition that would complicate study outcome data
- Pregnancy outcome diagnosed > 1 yr ago



#### **Main Infant Inclusion Criterion**

Born to mother enrolled in EMBRACE

#### **Infant Exclusion Criteria**

- Any condition that would complicate study outcome data
- Has reached 1 year birth date



#### **Maternal Visit Schedule**

- Screening/Enrollment
- Quarterly
- (Pregnancy Outcome)

#### **Infant Visit Schedule**

- Newborn/Initial Visit
- Months 1, 6 and 12



## MTN-016 Sites: 12 of 17

- Pittsburgh, US
- □ Zimbabwe 3 sites
- MRC, Durban, SA 7 sites
- Uganda
- RHRU
- PHRU
- eThekwini
- Aurum
- Birmingham, Alabama, US

#### **GOAL**

All 17 sites activated prior to January, 2011

PREFERABLY ... NOVEMBER 30, 2010